CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 13.92: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.52%
Annual Rate
CNY 0.20Paid annual
Payout Ratio
43.7%Sustainable
Last Ex-Dividend
Jul 15, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.49BCNY815.95M · vs all stocks (USD)
Revenue (TTM)
458.30MCNY68.07M · vs all stocks (USD)
Profit Margin
-0.77%Beta
-0.2300xvs all stocks
52-Week Change
23.38%vs all stocks
Market Capitalization
5.49BCNY815.95M · vs all stocks (USD)
Enterprise Value
4.48BCNY664.82M · vs all stocks (USD)
Price to Sales (TTM)
11.99xPrice to Book (MRQ)
2.56xEnterprise to Revenue
9.77xEnterprise to EBITDA
63.42xGross Margin
33.13%Profit Margin
-0.77%Operating Margin
4.11%Return on Assets (TTM)
-0.22%Return on Equity (TTM)
-0.17%Revenue (TTM)
458.30MCNY68.07M · vs all stocks (USD)
Revenue per Share (TTM)
3.03CNYUpdated Aug 20, 2026Quarterly Revenue Growth
68.10%Gross Profit (TTM)
142.93MCNY21.23M · vs all stocks (USD)
EBITDA (TTM)
28.46MCNY4.23M · vs all stocks (USD)
Net Income (TTM)
-3.52MCNY-523.36K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
43.51%Operating Cash Flow (TTM)
45.57MCNY6.77M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
11.76MCNY1.75M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2000CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.52%vs all stocks
Payout Ratio
43.67%Minority Interest (Equity)
2.61MCNYFY2025 · Dec 31, 2025Revenue
406.37MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
226.87MCNYFY2025 · Dec 31, 2025Gross Profit
179.50MCNYFY2025 · Dec 31, 2025Operating Income
13.48MCNY2.00M · vs all stocks (USD)
Pre-tax Income
-13.26MCNYFY2025 · Dec 31, 2025Income Tax Expense
-1.30MCNYFY2025 · Dec 31, 2025Net Income
-11.96MCNYFY2025 · Dec 31, 2025EBIT
-10.98MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
94.66MCNYFY2025 · Dec 31, 2025Research & Development
40.18MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
48.17MCNYFY2025 · Dec 31, 2025Other Operating Expenses
21.80MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.52MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.28MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0787CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0787CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
151.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
151.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-11.96MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
35.43KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-59.18MCNYFY2025 · Dec 31, 2025Free Cash Flow
-126.98MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
424.26MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-11.96MCNYFY2025 · Dec 31, 2025Other Non-cash Items
19.56MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-22.51MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-44.28MCNYFY2025 · Dec 31, 2025Capital Expenditures
-67.80MCNYFY2025 · Dec 31, 2025Purchase of Investments
-7.93BCNYFY2025 · Dec 31, 2025Sale of Investments
8.26BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
266.40MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
8.95MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-30.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-32.82MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-53.87MCNYFY2025 · Dec 31, 2025Shares Outstanding
154.71MSharesUpdated Aug 20, 2026Float Shares
80.79MSharesUpdated Aug 20, 2026% Held by Insiders
46.65%vs all stocks
% Held by Institutions
9.06%vs all stocks
Total Cash (MRQ)
964.14MCNY143.19M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.37CNYUpdated Aug 20, 2026Total Debt (MRQ)
59.11MCNY8.78M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0281xCurrent Ratio (MRQ)
7.57xBook Value per Share (MRQ)
13.87CNYUpdated Aug 20, 2026Total Assets
2.35BCNY349.00M · vs all stocks (USD)
Total Current Assets
1.30BCNYFY2025 · Dec 31, 2025Total Liabilities
252.83MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.05BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
49.87MCNYFY2025 · Dec 31, 2025Total Current Liabilities
202.97MCNYFY2025 · Dec 31, 2025Cash
725.80MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.52KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
725.80MCNYFY2025 · Dec 31, 2025Other Short-term Investments
270.08MCNYFY2025 · Dec 31, 2025Accounts Receivable
107.73MCNYFY2025 · Dec 31, 2025Inventory
148.43MCNYFY2025 · Dec 31, 2025Accounts Payable
164.63MCNYFY2025 · Dec 31, 2025Short-term Debt
14.81MCNYFY2025 · Dec 31, 2025Other Current Liabilities
270.16KCNYFY2025 · Dec 31, 2025Long-term Debt
44.30MCNYFY2025 · Dec 31, 2025Common Stock (Book)
154.71MCNYFY2025 · Dec 31, 2025Retained Earnings
269.66MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.10BCNY311.45M · vs all stocks (USD)
Treasury Stock
57.07MCNYFY2025 · Dec 31, 202552-Week Low
26.38CNYUpdated Aug 20, 202652-Week High
65.03CNYUpdated Aug 20, 202652-Week Change
23.38%vs all stocks
Beta
-0.2300xvs all stocks
50-Day MA
34.70CNYUpdated Aug 20, 2026200-Day MA
40.57CNYUpdated Aug 20, 2026Avg 10-Day Volume
15.30MSharesUpdated Aug 20, 2026Avg 30-Day Volume
11.65MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.0200CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 13.92: safe zoneNotable
Altman Z-Score: 13.92
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule
Esperion Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule